Latest research on G-CSF

Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue manufactured by recombinant DNA technology using a strain of E. coli. It is marketed as the brand name Neupogen by Amgen. Chemically, it consists of 175 amino acid residues. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine necessary for expression in E coli. Tbo-filgrastim, which is marketed by Sicor Biotech and FDA approved on August 29, 2012, contains the same active ingredient as Neupogen and is biologically similar, but it is formulated to be short-acting. On March 6, 2015, the FDA approved the biosimilar Zarxio (filgrastim-sndz) and is indicated for use in the same conditions as Neupogen. Zarxio is marketed by Sandoz.

G-CSF dosage

Patients received their current standard treatment which was supplemented only by administration of filgrastim (Neupogen, Amgen) at the following doses: 5 μg/kg of body weight/day for five consecutive days (course 1). [source, 2016]
The following data of each individual cycle administered were extracted: neutrophils, platelets, and hemoglobin levels at the time of cabazitaxel administration, prophylactic use of G-CSF (granulocyte colony-stimulating factor), total dose of cabazitaxel administered. [source, 2016]
mutation were able to form two- to threefold more colonies than healthy volunteers with wild-type RUNX1 in increasing doses of G-CSF (Figure 6a). [source, 2016]
For in vitro studies, bone marrow cells from C57 BL/6 mice were cultured with G-CSF (100 ng/mL) in the presence of super-low dose (100 pg/mL) or higher dose (1 μg/mL) LPS for 3 days, with fresh LPS added to the cell cultures every 24 h. [source, 2015]
Bone marrow cells from C57 BL/6 mice were cultured with G-CSF (100 ng/mL) in the presence of super-low dose (100 pg/mL) or higher dose (1 μg/mL) LPS, with fresh LPS added to the cell culture every 24 h. [source, 2015]
Subjects were randomized to receive Tbo-filgrastim 5 μg/kg administered as a single 30-minute intravenous infusion, placebo administered as a single 30-minute intravenous infusion, or Moxifloxacin 400 mg administered as a single oral dose. [source, 2015]
The dose and intravenous route of administration (30-minute infusion) of Tbo-filgrastim were chosen to achieve a systemic exposure higher than the expected therapeutic exposure following subcutaneous administration. [source, 2015]
Pharmacokinetic end points were evaluated in all subjects who received one dose of Tbo-filgrastim and had sufficient pharmacokinetic samples to allow accurate calculation (six or more samples covering absorption and elimination phases). [source, 2015]
In addition, the dose of Tbo-filgrastim selected for evaluation in the present study was an intravenous infusion of 5 μg/kg over 30 minutes. [source, 2015]
In the present study, the Cmax and AUC0–t for intravenous administration of 5 μg/kg of Tbo-filgrastim were 133.6 ng/mL and 516.5 h·ng/mL, respectively, similar to the values obtained in a previous study in which Tbo-filgrastim was administered intravenously at 5 μg/kg (129.8 ng/mL and 480.2 h·ng/mL, respectively) and greater than subcutaneous administration of Tbo-filgrastim at 5 μg/kg (18.0 ng/mL and 157.6 h·ng/mL, respectively),13 demonstrating that the expected exposure following the intravenous dose administered in the present study was significantly greater than the exposure following administration of the standard therapeutic dose recommended for Tbo-filgrastim. [source, 2015]